Company profile
Rapid Therapeutic Science Laboratories, Inc.
OTC: RTSL · Healthcare · Medical - Pharmaceuticals
#1162 of 1,417 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 44GM —SS 21
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$1.8M
Employees
3
as of 2026-08-31
Market cap
$3.5k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$1.8M-$1.8M2022
Operating income-$21.6k-$21.6k2017
Total assets$2.3M$2.3M2022
Liabilities$5.4M$5.4M2022
Equity-$3.1M-$3.1M2022
Revenue trend
FY2018 – FY2022 · USD
FY18
FY18
FY19
FY20
FY20
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rapid Therapeutic Science Laboratories, Inc.’s revenue?
Rapid Therapeutic Science Laboratories, Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
ForU Holdings, Inc.——Xeno Transplants Corporation——Claritas Pharmaceuticals, Inc.——Sienna Biopharmaceuticals, Inc.——Global Hemp Group Inc.——OncoVista Innovative Therapies, Inc.——Neighbors
Dallas →Key facts
CEODonal R. Schmidt Jr.
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersDallas, TX
ExchangeOTC: RTSL
Employees3
IPO date2017-06-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.